(Q42927505)

English

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

scientific article published on August 5, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma (English)

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Luis E Fayad

0 references

9

object named as

Larry W. Kwak

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735402

22 June 2024

author name string

Peter McLaughlin

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Barbara Pro

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Alma Rodriguez

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Michael Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Pamela Weaver

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kimberly Hartig

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Tatyana Feldman

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Judy Smith

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Peggy Ford

12

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Stuart Goldberg

13

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Andrew Pecora

14

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Andre Goy

15

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Jorge E. Romaguera

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735402

22 June 2024

language of work or name

0 references

publication date

5 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08315.x

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20735402

22 June 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.2010.08315.x

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.2010.08315.x

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

151

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

47-53

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

2

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

4

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clin

5

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

7

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma

10

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Real-time 5'-->3' exonuclease-based PCR assay for detection of the t(11;14)(q13;q32)

12

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Outcome of deferred initial therapy in mantle-cell lymphoma

13

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

14

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Severe pulmonary complications in African-American patient after bortezomib therapy

16

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Toxicity and response criteria of the Eastern Cooperative Oncology Group

17

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

18

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells

20

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma

21

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

22

1 reference

10.1111/J.1365-2141.2010.08315.X

https://api.crossref.org/works/10.1111/J.1365-2141.2010.08315.X

22 June 2024

Identifiers

10.1111/J.1365-2141.2010.08315.X

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42927505&oldid=2185963411"